Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. (Operator Instructions) I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of ...

During the recent period, Arrowhead (ARWR) signed and closed a potentially transformational licensing and collaboration agreement with Sarepta ...

PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR), currently trading at $20.24 and showing an 8% gain ...

The homebuilder recently acquired five plots of land along Scripps Ranch Boulevard and Meanley Drive from life science real ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacific Biosciences (PACB – Research ...

Brixmor Property Group Inc. ("Brixmor" or the "Company") announced today its operating results for the three and twelve months ended December 31, 2024.  For the three months ended December 31, 2024 ...